New tools for the development of direct NLRP3 inflammasome inhibitors

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1670909 since 2018-07-17T10:08:11Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
New tools for the development of direct NLRP3 inflammasome inhibitors

Marini E. (1), Giorgis M. (1) et Bertinaria M.*

(1) Dipartimento di Scienza e Tecnologia del Farmaco, Università degli studi di Torino, Via P. Giuria 9, 10125 Torino, Italy Affiliation and Address

In the last decades, several studies have highlighted the pivotal role of inflammasomes in the molecular control of inflammatory processes and the pathological role of NLRP3 inflammasome has been well established in different pathological settings. The discovery of agents able to prevent inflammasome activation is a promising therapeutic strategy to decrease chronic inflammation and associated damage. To date, different approaches have been pursued, among which reversible or irreversible modification of reactive cysteine residues of relevant proteins seems to be the prevalent one. In view of the above, we designed a library of electrophilic warheads bearing α,β-unsaturated nitrile and carbonyl-substituents. These compounds were able to significantly prevent NLRP3-dependent pyroptosis of THP-1 cells. We demonstrated via a thiol trapping kinetic assay and $^1$H NMR experiments that the biological activity of this series of compounds is dependent on their reactivity as Michael acceptors. The most promising warheads identified also proved able to directly inhibit the NLRP3 ATPase activity of isolated enzyme; unfortunately, these compounds exerted a certain degree of cytotoxicity on THP-1 cells, which could be related to their high reactivity. Thus, we developed new series of safer compounds by tuning down the reactivity of the electrophilic warhead through the chemical modulation of the acrylate scaffold. Thanks to this approach, we were able to obtain INF39 (11), a noncytotoxic molecule able to counteract NLRP3 activation through direct irreversible interaction with NLRP3 protein. We better investigated his mechanism of action, and 11 has revealed able to block the conformational change required for inflammasome activation (Bioluminescence Resonance Energy Transfer experiment on recombinant NLRP3). Our preliminary in vitro ADME studies showed that INF39 was stable in simulated gastric and intestinal fluids, and it was absorbed into the intestinal epithelium, where it can act locally and generate a nontoxic active metabolite. On the basis of the preliminary ADME profile, INF39 was selected for in vivo studies in a model of DNBS-induced colitis in rats. After oral administration, INF39 significantly reduced systemic and colonic inflammation.


* contact : massimo.bertinaria@unito.it